Navigation Links
Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
Date:12/20/2013

the Board, commented: "I am delighted to welcome Annika to Symphogen. Annika's extensive experience in both the healthcare industry and financial markets makes her a perfect addition to the Board.  Annika's skills, knowledge and experience will be invaluable to furthering the success of Symphogen."

Annika Espander Jansson added: "I am very excited to take part in the development of Symphogen which operates in a very important medical area with significant unmet medical needs and with a business concept aiming at improving therapies for cancer patients."

About Symphogen A/S  

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market.

The company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The company has matured its oncology pipeline and has currently brought two product candidates into the clinic. The company's productive technology suite - capable of identifying, selecting and manufacturing optimal antibody mixtures - fuels Symphogen's innovative pipeline.

The lead oncology product, Sym004, was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.

In total, the company has raised €249 million in equity capital from premier international investors including Novo, Essex Woodlands Health Ventures and PKA, and employs 95 people, most of whom are based at Symphogen's facilities in Copenhagen.

For additional information, please contact:
Kirsten Drejer
Chief Executive Officer
Phone: +45-22-10-99-59
E-mail: kd@symphogen.com

Martin Olin
Chief Financial Officer
Phone:
'/>"/>

SOURCE Symphogen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
3. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
4. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
5. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
6. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
7. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
8. Pittcon Announces the 2014 Technical Program
9. AudioNotch Tinnitus Treatment Announces Holiday Sale
10. Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
11. DryLet, LLC Announces Investment from Ronald A. Chisholm Limited to Support Growth and Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  A novel biomarker for ... physicians better identify early-stage disease, when treatment can ... to a new study in The Journal of ... DGX ) and other institutions found ... outperformed conventional antibody-serum testing, including rheumatoid factor (RF) ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 “We are ... technology vendors,” said Ven Thangaraj, CEO of Radiant Sage. ... that are taking the imaging corelab market to a ... corelabs and research organizations to efficiently and effectively manage ... the data to be analyzed and read by trained ...
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, the ... today announced the hiring of veteran equity analyst Charles ... analyst. Mr. Butler will focus on the biotech/biopharma sector. ... a wealth of experience and a broad network of ... Senior Managing Director and Head of Equities at Guggenheim ...
(Date:8/27/2014)... -- Reportbuyer.com has added a new market research ... Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... similar amount of hype currently surrounds graphene, with ... water treatment, but is graphene the only solution? ... Opportunity Report, authored by Tim Harper ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... While the great rock concert halls and rock festivals of ... these musical Meccas continues (mostly in the form of Farewell ... the wild 1980s and 1990s is celebrated every year in ... that lead the charge in promoting the hot biotech companies ...
... the first thing to do when draining a swamp is ... to an information swamp. Information not only needs to be ... also as its passed within an organization. IT shops are ... systems and even the old, back office systems running on ...
... organizations can increase their productivity and be more responsive ... the quality of the care they provide as a ... , a Hartford, Wis.-based software company. API Software announced ... Station (EIS) and its ActiveStaffer scheduling application, which recently ...
Cached Biology Technology:The Biotech Concert Halls of the Decade of 2000 2Draining the Information Swamp 2Draining the Information Swamp 3API Releases New Software, Acquires Additional Contracts 2
(Date:8/26/2014)... Animals (PETA) and the PETA International Science Consortium, LTD ... the 9th World Congress on Alternatives and Animal Use ... to the use of animals in research, testing and ... current laboratory oversight systems. , At the conference, which ... PETA and PISC will present seven oral and poster ...
(Date:8/25/2014)... has experienced widespread adoption of robot-assisted prostate removal ... The BJU International study also found ... traditional surgeries, their costs are decreasing over time. ... in operations to remove the prostate. To examine ... prostatectomy (RARP) procedures for prostate cancer patients, Steven ...
(Date:8/25/2014)... old saying in the biofuels industry: "You can ... a new study may pave the way to ... Department,s National Renewable Energy Laboratory (NREL) demonstrates a ... of lignin into a variety of renewable fuels, ... , " Lignin Valorization Through Integrated Biological Funneling ...
Breaking Biology News(10 mins):US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate 2New process helps overcome obstacles to produce renewable fuels and chemicals 2
... international team of scientists, with Spanish participation, has shed ... documenting these acts for the first time in the ... cannot raise their infants without help from male group ... death of their offspring if they are stressed and ...
... singer hitting a note that shatters a glass, a ... in a material and change its properties. And as ... can change the critical pitch. Echoing both phenomena, researchers ... have demonstrated a unique fluid-tuned "metasurface," a concept that ...
... David Litchfield of The University of Western Ontario has ... cells to allow these cells to ignore,signals that should ... cancer cells may become resistant to therapy. The ... http://stke.sciencemag.org/cgi/content/full/sigtrans;4/172/ra30 ). "This work focused on understanding ...
Cached Biology News:Competition between females leads to infanticide in some primates 2NIST tunes 'metasurface' with fluid in new concept for sensing and chemistry 2
...
More cell-permeant than acridine orange....
Anti-rat Ig HRP detection kit...
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
Biology Products: